Duration of SARS-CoV-2 sero-positivity in a large longitudinal sero-surveillance cohort: the COVID-19 Community Research Partnership
| Autor: | Allison Mathews, Karen L. Kotloff, Adolfo Correa, Austin L. Seals, Lewis McCurdy, Alain G. Bertoni, Sharon L. Edelstein, Michael A. Gibbs, John W. Sanders, Mark A. Espeland, DeAnna Friedman-Klabanoff, Diane Uschner, David M. Herrington, Michael S. Runyon, Thomas F. Wierzba, Michele Santacatterina, Martha Alexander-Miller, William S. Weintraub, Iqra Munawar |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Coronavirus disease 2019 (COVID-19) business.industry SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Research COVID-19 Infectious and parasitic diseases RC109-216 Antibodies Viral Infectious Diseases General partnership Immunoglobulin G Cohort Sero-surveillance Medicine Humans Humoral response Duration (project management) business Pandemics Demography Sero surveillance |
| Zdroj: | BMC Infectious Diseases BMC Infectious Diseases, Vol 21, Iss 1, Pp 1-11 (2021) |
| ISSN: | 1471-2334 |
| Popis: | Background Estimating population prevalence and incidence of prior SARS-CoV-2 infection is essential to formulate public health recommendations concerning the COVID-19 pandemic. However, interpreting estimates based on sero-surveillance requires an understanding of the duration of elevated antibodies following SARS-CoV-2 infection, especially in the large number of people with pauci-symptomatic or asymptomatic disease. Methods We examined > 30,000 serology assays for SARS-CoV-2 specific IgG and IgM assays acquired longitudinally in 11,468 adults between April and November 2020 in the COVID-19 Community Research Partnership. Results Among participants with serologic evidence for infection but few or no symptoms or clinical disease, roughly 50% sero-reverted in 30 days of their initial positive test. Sero-reversion occurred more quickly for IgM than IgG and for antibodies targeting nucleocapsid protein compared with spike proteins, but was not associated with age, sex, race/ethnicity, or healthcare worker status. Conclusions The short duration of antibody response suggests that the true population prevalence of prior SARS-CoV-2 infection may be significantly higher than presumed based on earlier sero-surveillance studies. The impact of the large number of minimally symptomatic COVID-19 cases with only a brief antibody response on population immunity remains to be determined. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|